

# FOURIER: Primary Results of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

**Purpose:** In patients with cardiovascular disease on statins, to evaluate whether the use of an additional LDL-C-lowering agent (evolocumab) added to statin therapy will reduce the risk of adverse cardiovascular events.

**Trial Design:** Double-blinded, placebo-controlled, randomized. N=27,564. Evolocumab + statin vs placebo + statin in patients on statins with LDL-C  $\geq$  70 mg/dL. [Evolocumab 140 mg q 2 wks. or 420 mg/month.]

**Primary Endpoint:** Composite: cardiovascular events over 5 years of f/u: death, MI, hospitalization for stroke, angina, coronary revascularization.

Trial Results @ 48 weeks	Composite endpoint risk reduction	P value
Evolocumab + statin	9.8%	<0.001
Placebo	11.3%	

**Conclusions:** Evolocumab added to statin therapy in these patients lowered LDL-C and reduced cardiovascular events.

